OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Financial Statements and ExhibitsItem 9.01. Financial Statements and Exhibits
(d) Exhibits
|
1.1 |
Underwriting Agreement, dated August 14, 2017, between Oxford Immunotec Global PLC and BTIG, LLC. |
|
5.1 |
Opinion of Covington & Burling LLP. |
|
23.1 |
Consent of Covington & Burling LLP (included in Exhibit 5.1). |
Oxford Immunotec Global PLC ExhibitEX-1.1 2 ex1-1.htm EXHIBIT 1.1 ex1-1.htm Exhibit 1.1 Execution Version OXFORD IMMUNOTEC GLOBAL PLC 2,…To view the full exhibit click here
About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.